Titan Biotech Limited (BOM:524717)
India · Delayed Price · Currency is INR 366.40
+16.80 (4.81%)
At close: Nov 9, 2026
Titan Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 2,410 | 2,062 | 1,565 | 1,641 | 1,440 | 1,235 |
| 2,410 | 2,062 | 1,565 | 1,641 | 1,440 | 1,235 | |
Revenue Growth | 38.25% | 31.79% | -4.64% | 13.94% | 16.55% | -13.14% |
Cost of Revenue | 1,164 | 985.38 | 741.94 | 769.36 | 710.43 | 598.28 |
Gross Profit | 1,246 | 1,077 | 822.57 | 871.36 | 729.57 | 637.21 |
Selling, General & Admin | 402.05 | 362.37 | 310.18 | 267.96 | 209.68 | 148.78 |
Other Operating Expenses | 361.62 | 325.97 | 259.6 | 262.02 | 225.04 | 176.6 |
Operating Expenses | 819.85 | 741.23 | 611.47 | 563.29 | 461.52 | 349.08 |
Operating Income | 426.33 | 335.3 | 211.1 | 308.08 | 268.05 | 288.13 |
Interest Expense | -6.49 | -5.9 | -4.4 | -7.96 | -4.5 | -5.99 |
Interest & Investment Income | 7.37 | 7.37 | 5.1 | 0.86 | 0.44 | 1.13 |
Earnings From Equity Investments | 34.51 | 24.38 | 32.61 | 11.9 | 38.19 | - |
Other Non Operating Income (Expenses) | 48.13 | 33.27 | 26.25 | 8.69 | 16.68 | 6.44 |
EBT Excluding Unusual Items | 509.86 | 394.43 | 270.65 | 321.56 | 318.87 | 289.71 |
Gain (Loss) on Sale of Investments | 11.7 | 11.7 | 5.63 | 5.63 | 0.49 | - |
Gain (Loss) on Sale of Assets | - | - | - | - | - | -0.02 |
Pretax Income | 521.55 | 406.13 | 276.28 | 327.19 | 319.35 | 289.69 |
Income Tax Expense | 134.93 | 107.27 | 60.96 | 78.66 | 70.91 | 72.85 |
Earnings From Continuing Operations | 386.62 | 298.85 | 215.32 | 248.53 | 248.44 | 216.84 |
Net Income | 386.62 | 298.85 | 215.32 | 248.53 | 248.44 | 216.84 |
Net Income to Common | 386.62 | 298.85 | 215.32 | 248.53 | 248.44 | 216.84 |
Net Income Growth | 67.63% | 38.80% | -13.36% | 0.03% | 14.57% | -28.52% |
Shares Outstanding (Basic) | 46 | 52 | 52 | 52 | 52 | 52 |
Shares Outstanding (Diluted) | 46 | 52 | 52 | 52 | 52 | 52 |
Shares Change | -9.98% | - | - | - | - | - |
EPS (Basic) | 8.31 | 5.79 | 4.17 | 4.81 | 4.81 | 4.20 |
EPS (Diluted) | 8.31 | 5.78 | 4.17 | 4.81 | 4.81 | 4.20 |
EPS Growth | 86.16% | 38.77% | -13.37% | 0.02% | 14.57% | -28.52% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 209.1 | 229.93 | 116.03 | 16.61 | 84.45 | 157.29 |
Free Cash Flow Per Share | 4.50 | 4.45 | 2.25 | 0.32 | 1.64 | 3.04 |
Dividend Per Share | - | 0.400 | 0.320 | 0.320 | 0.288 | 0.240 |
Dividend Growth | - | 25.00% | 0% | 11.11% | 20.00% | 0% |
Gross Margin | 51.72% | 52.21% | 52.58% | 53.11% | 50.66% | 51.58% |
Operating Margin | 17.69% | 16.26% | 13.49% | 18.78% | 18.62% | 23.32% |
Profit Margin | 16.05% | 14.49% | 13.76% | 15.15% | 17.25% | 17.55% |
Free Cash Flow Margin | 8.68% | 11.15% | 7.42% | 1.01% | 5.86% | 12.73% |
EBITDA | 473.09 | 378.76 | 248 | 336.52 | 289.21 | 307.71 |
EBITDA Margin | 19.63% | 18.37% | 15.85% | 20.51% | 20.08% | 24.91% |
D&A For EBITDA | 46.76 | 43.46 | 36.9 | 28.44 | 21.16 | 19.58 |
EBIT | 426.33 | 335.3 | 211.1 | 308.08 | 268.05 | 288.13 |
EBIT Margin | 17.69% | 16.26% | 13.49% | 18.78% | 18.62% | 23.32% |
Effective Tax Rate | 25.87% | 26.41% | 22.07% | 24.04% | 22.20% | 25.15% |
Revenue as Reported | 2,479 | 2,116 | 1,604 | 1,658 | 1,459 | 1,245 |
Advertising Expenses | - | 33.07 | 40.72 | 26.12 | 26.42 | 5.48 |